Research
Hormonal
GLP-2 administration promotes intestinal epithelial proliferation and regeneration, reducing apoptosis and improving outcomes in models of intestinal injury such as enteritis and mucositis.
GLP-2 helps the gut lining grow back and repair itself after injury from drugs or disease. This suggests potential utility in treating inflammatory bowel disease or chemotherapy-induced gut damage.
GoodSupportsHIGH confidence
GLP-2 administration significantly improves morbidity and enhances epithelial repair in a diverse number of injury models, including enteritis and mucositis... GLP-2 expands the villous epithelium predominantly through stimulation of crypt cell proliferation.
Why this rating
Based on multiple animal models of intestinal injury summarized in the review.
Source
Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System
Patricia L. Brubaker et al. · Endocrinology · 2004
DOI 10.1210/en.2004-0015
narrative_reviewCited 545×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of the GLP-1 receptor promotes pancreatic beta-cell proliferation and inhibits apoptosis, leading to expanded beta-cell mass and improved glucose tolerance in diabetic animal models.Good
- GLP-1 receptor activation inhibits beta-cell apoptosis through cAMP/PKA and PI3K/Akt signaling pathways, protecting beta-cells from cytokine and fatty acid-induced death.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →